Effects of GABA Modulator AZD7325 on Cortical Excitability

Inclusion Criteria: * Male adults aged 18 to 55 years (extremes are included) * A body weight resulting in a body mass index (BMI) of 18 - 30 kg/m2 (extremes included) using the formula BMI = body-weight \[in kg\] / body-height \[in m\]2 * Able and willing to sign the Informed Consent Form prior to screening evaluations * History of good physical and mental health as determined by history taking and laboratory examinations, ECG, blood pressure and heart rate recordings as judged by the investigator * Willing not to consume alcohol or to smoke or chew tobacco on days of assessments * Subjects must be willing to avoid unprotected sex or donating sperm until 3 weeks after drug administration Exclusion Criteria: * History of sensitivity/idiosyncrasy to AZD7325 or chemically related compounds or excipients which may be employed in the study or to any other drug used in the past * Subject has taken systemically any potent or moderate CYP3A4 or CYP2C9 inhibitor, 1 month prior to screening (topical or inhaled are permitted) such as: aprepitant, barbiturates, carbamazepine, clarithromycin, erythromycin, cyclosporine, diltiazem, efavirenz, fluconazole, HIV protease inhibitors, glucocorticoids, itraconazole (oral/IV), ketoconazole, nefazodone, nevirapine, phenytoin, pioglitazone, primidone, rifabutin, rifampicin, telithromycin, St. John's wort, verapamil * Use of any prescription drug within two weeks prior to the first dosing, except for topical medication without systemic exposure * Clinically relevant history or presence of any medical disorder, potentially interfering with this trial * Clinically relevant abnormal laboratory, ECG, HR or BP at screening as judged by the investigator * History of or current abuse of drugs (including prescription medication) or alcohol or solvents * Smoking in excess of 5 cigarettes per day or the equivalent within 28 days prior to the first study day * Smoking or chewing of tobacco or consuming of alcohol 24 hours before and on the days of assessment * Subject is family member or in the employment line management of study personnel * Subject's partner is planning pregnancy within 3 months of last dosing * Participation in an investigational medicinal product (IMP) intervention trial within last month or more than four in the previous 12 months * Abnormal SICI response, kinematic analysis of circle drawing, SDMT, VAS outside 95% confidence interval of normal at screening visit * Contraindications for TMS